Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jacob M SadlerInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0009-0001-6430-608X
Alfred SimkinDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.ORCID 0000-0001-9408-0053
Valery P K TchuenkamDepartment of Biochemistry, Faculty of Science, University of Dschang, Dschang, West Region, Cameroon.
Isabela Gerdes GyuriczaInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-7969-1910
Abebe A FolaDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.ORCID 0000-0001-5392-2859
Ashenafi AssefaInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-0147-9362
Karamoko NiaréDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.ORCID 0000-0002-7406-9508
Kyaw ThwaiInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Samuel J WhiteInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
William J MossDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
Rhoel R DinglasanEmerging Pathogens Institute, University of Florida, Gainesville, Florida, United States of America.ORCID 0000-0001-5433-8179
Christopher B TumeDepartment of Biochemistry, Faculty of Science, University of Dschang, Dschang, West Region, Cameroon.
Jonathan B ParrInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-4465-9830
Innocent Mbulli AliDepartment of Biochemistry, Faculty of Science, University of Dschang, Dschang, West Region, Cameroon.ORCID 0000-0002-1112-6376
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island.ORCID 0000-0002-6899-8204
Jonathan J JulianoInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-0591-0850
Funding
TransmissionU19AI089680 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WILLIAM J MOSS · 2010 to 2026
$25.6M
Relapsing malaria in Africa: mechanisms for persistence amid falciparum declineR01AI165537 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Rhoel David Ramos Dinglasan, Jonathan J Juliano · 2022 to 2026
$3.6M
Epidemiology and determinants of emerging artemisinin-resistant malaria in EthiopiaR01AI177791 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan Boyd Parr · 2023 to 2026
$3.2M
Artemisinin Resistance in Africa: its emergence and evolution in RwandaR01AI156267 · NIAID · BROWN UNIVERSITY · PI BAILEY, JEFFREY A., JULIANO, JONATHAN J · 2021 to 2024
$3.0M
Importation and transmission of malaria in Zanzibar: a case study for eliminationR01AI155730 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J, LIN, JESSICA · 2021 to 2024
$2.8M
Mentoring in Translational Malaria GenomicsK24AI134990 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan J Juliano · 2018 to 2026
Background: Resistance to antimalarial drugs remains a major obstacle to malaria elimination. Multiplexed, targeted amplicon sequencing is being adopted for surveilling resistance and dissecting the genetics of complex malaria infections. Moreover, genotyping of parasites and detection of molecular markers drug resistance in resource-limited regions requires open-source protocols for processing samples, using accessible reagents, and rapid methods for processing numerous samples including pooled sequencing. Methods: Results: We evaluated Conclusion: Overall,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Application of a new highly multiplexed amplicon sequencing tool to evaluate · full record | OpenQuestion